JKTG Founder and President Ted Giovanis, leading researchers, and University leaders gathered at the Johns Hopkins Welch Medical Library this week to formally mark the dedication of the Giovanis Institute for Translational Cell Biology – a symbolic first step of this important cancer research program.
Through a $35M, 15-year gift from Giovanis, researchers will tackle the most fatal aspect of cancer: how it metastasizes, or spreads, through the body. Key to this work is collaboration among many disciplines, including biology, clinical treatment of patients, physics, engineering, machine learning, and computational medicine.
“I strongly believe that tackling hard questions and inviting collaboration across disciplines empowers new thinking among researchers who, I believe, can transform how we diagnose and treat cancer,” said Giovanis.
Video
Gallery
Featured news
Applying nanoparticles and the immune system to fight cancer
JKTG-funded research, Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer, appears in the journal ACS Nano and features a collaboration between researchers at Johns Hopkins University School of Medicine and the Hormel Institute at the University of Minnesota.
Ted’s Take: It’s about the money
Money is what seems to drive things and money is what seems to drive organizations too. They all start with an overriding moral goal but after a while things often turn toward more money.
Ted’s Take: The best patient advocate? You.
When you’re a patient, you are kind of vulnerable. You have a problem, are often sketchy about what it is and the potential treatment or therapy needed. The bigger the problem, the more vulnerable you are. This makes you a perfect advocate.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133